Cochrane · systematic review · CD012188
Gabapentin for fibromyalgia pain in adults
Cooper, TE, Derry, S, Wiffen, PJ, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Gabapentin compared with placebo for fibromyalgia
Population: adults with fibromyalgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
30% pain reduction at 12 weeks Gabapentin vs placebo | no estimate extracted | 1 study · 150 participants | Very low |
50% pain reduction at 12 weeks Gabapentin vs placebo | no estimate extracted | NR | Very low |
PGIC ‐ any category of "better" at 12 weeks Gabapentin vs placebo | no estimate extracted | 1 study · 150 participants | Very low |
Withdrawals due to adverse events Gabapentin vs placebo | no estimate extracted | 1 study · 150 participants | Very low |
Serious adverse events Gabapentin vs placebo | no estimate extracted | 1 study · 150 participants | Very low |
Deaths Gabapentin vs placebo | no estimate extracted | 1 study · 150 participants | Very low |